Navigation Links
Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug

TSX-V: PGA

VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - Pacgen Biopharmaceuticals Corporation ("Pacgen") is pleased to report that topline results from its Phase I/II study of PAC-113, a novel antifungal, show it is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. Based on these results the Company plans to initiate a Phase IIb study to optimize PAC-113 dose and formulation.

"For many immunocompromised patients oral candidiasis can be severe, impacting their ability to get appropriate nutrition. We are very encouraged by the PAC-113 results and its potential to help patients with oral candidiasis, particularly when available treatments have a number of limitations and drawbacks," said Dr. Neil Reiner, Professor and Head of Division of Infectious Diseases, UBC Department of Medicine and Vancouver General Hospital, and a member of Pacgen's Clinical Advisory Board

PAC-113 is a peptide based anti-fungal drug candidate targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. The Phase I/II clinical trial of PAC-113 was conducted at sites in the United States and South Africa and recruited over 100 HIV seropositive patients with oral candidiasis.

The objective of this study was to provide safety data for PAC-113, as well as to establish first proof of efficacy for PAC-113 in eliminating clinical signs and symptoms of oral candidiasis. This Phase I/II study was a comparison between PAC-113 mouthrinse and Nystatin oral suspension. The study was a randomized, examiner-blinded, parallel design clinical trial that included a 14-day treatment phase, and a 14-day follow-up period, with a day 28 follow-up visit. Analyses were conducted on patients who were at least 80% compliant in the treatment phase.

Topline results show that 37% of PAC-113
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/21/2013)... 2013 Kepner-Tregoe (KT), the global capability ... veteran Chris Geraghty has ... more than 20 years serving the industrial sector, ... He succeeds Ray Baxter , ... of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  Armada Health ... of the new Armada corporate website ( www.armadahealthcare.com ... communicate Armada,s unique and first-to-market services and its ... focused on the specialty pharmacy industry. ... of the Armada business model in delivering an ...
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
(Date:5/21/2013)... 2013 The In View series ... and cable channels across the country, announces it has ... channel. The producers of the series proudly bring audiences ... industry, the manufacturing industry, health-related companies, medical facilities and ... medical practitioners in all parts of the United States, ...
(Date:5/21/2013)... 2013 Global Proving Ground (GPG), a ... largest online retailer of health and fitness supplements, are ... show, Warrior Island. “We cast the show by ... Twitter, with our unique social networking platform,” states show’s ... fighters on an island in the Pacific Ocean, where ...
(Date:5/21/2013)... A paper recently published in the New England ... scientists at the University of Colorado School of Medicine ... fibrosis can be used to identify individuals at risk ... a fairly common variant of the gene for mucin-5B, ... produced by the bronchial tubes. While this variant of ...
(Date:5/21/2013)... Department of Defense Serum Repository (DoDSR), University of Cincinnati ... inflammatory bowel disease (IBD), which could help with earlier ... shown symptoms. , This finding, the first of its ... being presented via podium presentation by staff from Walter ... 2013, being held May 18-21 in Orlando, Fla. ...
(Date:5/21/2013)... 21, 2013 The nation’s first trial ... is nearing its conclusion in Washington state court, Bernstein ... statements yesterday, an attorney for the Plaintiffs compared Intuitive ... to tie sales and services for its customers. ... keep control of surgeons, to keep control of hospitals ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: